^
Association details:
| Biomarker: | KIT exon 11 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
To compare the efficacy of sunitinib and imatinib following cytoreductive resection in GIST patients with progression on imatinib: A multi-center controlled study.
Published date:
05/16/2018
Excerpt:
Patients carrying a primary KIT exon 11 mutation had a PFS of 31 months in sunitinib compared with 11 months in imatinib (p = 0.036), respectively. The PFS of sunitinib group was longer than that of imatinib group (30.0 months vs 12.0 months, p = 0.009).
DOI:
10.1200/JCO.2018.36.15_suppl.11530
